In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians.
Promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test.
Dr. Skibo discusses how ddPCR-based liquid biopsy could become an indispensable method for doctors to categorize a patient’s disease.
Article from Global Engage, interviewing Dr. Gary Pestano and Dr. Hestia Mellert about the future of droplet digital PCR.
Dr. Paul Walker describes how liquid biopsy testing helps battling lung cancer in the tobacco belt. The advantages of liquid biopsy for lung cancer.